Neoadjuvant Chemoimmunotherapy Deemed Safe, Effective in Esophageal Cancer
Neoadjuvant chemotherapy combined with an immune checkpoint inhibitor is safe and effective in patients with resectable esophageal cancer, a real-world study suggests.
Neoadjuvant chemotherapy combined with an immune checkpoint inhibitor is safe and effective in patients with resectable esophageal cancer, a real-world study suggests.
Patients with LS-SCLC have better survival outcomes at 1 year and 5 years if they undergo surgical resection, a large study suggests.
An analysis of lung cancer specimens revealed the strongest SGLT2 expression in carcinoid tumors, adenosquamous carcinomas, and adenocarcinomas.
A multidisciplinary treatment approach can produce favorable outcomes in patients with superior sulcus NSCLC, according to researchers.
Station 9 lymph nodes should be sampled for primary non-small cell lung cancer of the middle and lower lobes, according to researchers.
Patients with non-small cell lung cancer may have a 3-fold higher risk of death if they develop COVID-19, a study suggests.
Salvage resection may benefit patients with NSCLC who have residual or recurrent disease after immunotherapy, a study suggests.
Induction with alectinib or crizotinib is clinically feasible in ALK-positive, stage III non-small cell lung cancer, according to researchers.
Several groups of patients are underrepresented in NSCLC clinical trials, new research suggests.
Reductions in air pollutants coincided with reductions in lung cancer incidence in a Michigan county, researchers found.